- EU Opens Probe in BHP Billiton Bid for Rio Tinto
- Worse Car Sales Decline Expected in Western Europe
- Euro Banks Need to Raise $90-$140 Billion: Goldman
- BSkyB Mulls $4 Billion Bid for Spain's Digital Plus: FT
- On the Bright Side, Shopping Bargains Abound
- Euro Stocks Fall as Goldman Note Hits Banks
- Return of Asian Currency Crisis Is Unlikely: ADB
- European Shares Set to Open Flat as Holiday Shuts US
- Airbus to Sell Five A380s to Japan's ANA: Nikkei
- Bowyer: Back to Monarchy in Land Rights?
- Parking Cash in European Telecoms
- Bargain Stocks: Nokia, Spectra, Incitex Pivot
- Sticker Shock: Fast Money's Inflation Special
- Our Favorite Inflation Trades
- Warren Buffett's Annual Stock Gift to Gates Foundation Worth $1.8B This Year
- That '70's Trade
- The Villain Of Our Story
- The Blame Game
![]() |
David Spika, WHG Funds vice president, isn't afraid to use the "R" word -- but he's no bear. He thinks the recession talk is overdone, making now a great time to buy stocks.
Jeff Krumpelman of Fifth Third Asset Management also hears opportunity knocking.
"I think the market is confused and nervous about how far left or right we are of zero," Krumpelman told CNBC.
"So we'll have continued volatility while it's figuring that out. But if you ask me over the next nine to 12 months if I thought this is a good time to be building positions, absolutely, I think it is."
Investor Takeaway: |
"The market's pretty much priced into a recession, and priced into a pretty significant recession," Spika said. "Regardless of whether we have one, now is a good time to buy."
So what buys look good? He likes The Walt Disney Co. [DIS
Loading...
()
]
"If the economy goes into a significant, protracted recession, consumer-related stocks are going to get hurt -- but we don't think that's the case, and Disney's trading at a 20-year low valuation right now," Spika said.
"We think we'd be stupid not to be buying it here."
Does Market Agree? |
Krumpelman's confidence extends all the way to biotechnology. One biotech stock that he likes even better than pharmaceuticals: Celgene [CELG
Loading...
()
].
"I think it's misleading just to say, let's flock to large-cap pharmaceutical companies that have very unimpressive growth rates." he said. "I feel much safer with...Celgene."
He said the company "has a strong franchise, with a 35 percent growth profile."





